In the Journals

Early adverse events spur depression, health concerns in teens

November 17, 2017
Children who experience an increase of zero to three adverse childhood events, including poverty or traumatic events, were 25% more likely to have…
In the Journals

Antipsychotic use in young children declines following peer review policy

November 17, 2017
Following implementation of the peer review prior authorization policy, atypical antipsychotic use significantly decreased among children aged…
In the Journals

Data shows long-term efficacy, safety of Ingrezza for tardive dyskinesia

November 17, 2017
Full long-term findings, indicating efficacy and safety of Ingrezza for tardive dyskinesia, were recently published in Journal of Clinical
In the Journals

Depression in fathers linked to teen depression

November 16, 2017
Greater depressive symptoms among fathers were associated with greater depressive symptoms among their adolescent children, according to study…
In the Journals

Speed processing training lowers dementia risk

November 16, 2017
Speed of processing training decreased risk for dementia, while memory and reasoning training did not, according to recent findings. “Speed of…
Meeting News

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

November 16, 2017
WASHINGTON — When diagnosed with
In the Journals

Discrimination contributes to depression in black men

November 16, 2017
Daily discrimination was independently associated with depression among black men. “Few studies have focused on African-American men to…
In the Journals

Opioid abuse treatment medications equally effective

November 15, 2017
Buprenorphine-naloxone combination and extended-release naltrexone were both safe and effective in managing patients with opioid use disorder…
Meeting News

AMA adopts new strategy for genetic tests, therapeutics

November 15, 2017
AMA recently voted to advance the development of a comprehensive strategy that allows more consistent coverage of genomic and genetic tests and…
FDA NewsPerspective

FDA authorizes marketing of device to reduce opioid withdrawal symptoms

November 15, 2017
The FDA granted marketing authorization of an electronic stimulation device to aid in reducing the symptoms associated with opioid withdrawal. The…
In the Journals

OCD may hinder performance, success in school

November 15, 2017
Individuals with obsessive-compulsive disorder performed poorer in school and were less likely to finish upper secondary education, start or finish a…

Nexalin explores transcranial stimulation for major depression

November 15, 2017
Nexalin Technology recently announced initiation of clinical trials, designed by researchers at the University of Pennsylvania, to assess efficacy of…
In the Journals

Social media use does not harm mental health

November 14, 2017
Time spent on social media was not associated with negative mental health outcomes among young adults; however, posting vague yet alarming…
FDA News

Vraylar receives FDA approval for maintenance schizophrenia treatment

November 14, 2017
Allergan recently announced that the FDA approved a supplemental New Drug Application for Vraylar for maintenance treatment of schizophrenia. …

FDA warns against use of kratom

November 14, 2017
The FDA issued a warning today about the potentially fatal risks linked to kratom, a plant-based product from Asia that the agency said is used to…
FDA News

FDA approves Abilify MyCite, digital pill to track medication ingestion

November 14, 2017
The FDA recently approved Abilify MyCite, aripiprazole tablets with an ingestible sensor from Otsuka Pharmaceuticals and Proteus Digital Health, to…

Experts discuss changing scope of insomnia treatment

November 14, 2017
Improving sleep hygiene has long been recommended as a treatment for insomnia, but there is increasing evidence that it is insufficient as standalone…
In the Journals

Long-term acetaminophen use during pregnancy linked to ADHD in children

November 14, 2017
Although short-term use of acetaminophen for pregnant women was not associated with a future ADHD diagnosis in their offspring, long-term maternal

Trump nominates former pharmaceutical executive for HHS secretary

November 13, 2017
President Donald J. Trump has nominated Alex Azar II, the head of pharmaceutical company Eli Lilly’s U.S.-based operations until this past…

Brexanolone effective for moderate, severe postpartum depression

November 13, 2017
Sage Therapeutics recently announced phase 3 findings that indicated efficacy and safety of brexanolone, formerly known as SAGE-547, for postpartum…
Advertisement
Advertisement